Improved T Cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Demographics (2)
- AGE - Subject age at enrollment (phv00500043.v1.p1)
- SEX - Biological sex (phv00500039.v1.p1)
Other (11)
- Analyte_Type - Analyte Type (phv00500045.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00500038.v1.p1)
- IS_TUMOR - Tumor status (phv00500046.v1.p1)
- SAMPLE_ID - Sample ID (phv00500044.v1.p1)
- SAMPLE_ID - Sample ID (phv00500041.v1.p1)
- SAMPLE_TIMEPOINT - Timepoint of sample collection (phv00500047.v1.p1)
- SEQUENCING_CENTER - Center that performed sequencing (phv00500049.v1.p1)
- SUBJECT_ID - Subject ID (phv00500037.v1.p1)
- SUBJECT_ID - Subject ID (phv00500040.v1.p1)
- SUBJECT_ID - Subject ID (phv00500042.v1.p1)
- TUMOR_GRADE - Tumor grade of sample (phv00500048.v1.p1)